Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is trading higher on Friday after the company issued upbeat guidance for 2024 and 2025 and better-than-expected second-quarter earnings. On Thursday, the cancer cell therapy maker Iovance reported second-quarter sales of $31.12 million, surpassing the consensus of $24.6 million. The company reported EPS loss of $(0.34), down from $(0.47) a year ago, beating the consensus of $(0.35). Also Read: Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy. The second quarter of 2024 represents the first quarter of Amtagvi (lifileucel) sales in the U.S., with revenue of ...